Effects of telbivudine treatment on the circulating CD4⁺ T-cell subpopulations in chronic hepatitis B patients.
Effects of telbivudine treatment on the circulating CD4⁺ T-cell subpopulations in chronic hepatitis B patients.
复制标题
替比夫定治疗对慢性乙型肝炎患者循环 CD4 T 细胞亚群的影响
DOI：
10.1155/2012/789859
复制
发表时间：
2012
影响因子：
4.6
通讯作者：
Wu Y
中科院分区：
文献类型：
--
作者：
Zheng Y;Huang Z;Chen X;Tian Y;Tang J;Zhang Y;Zhang X;Zhou J;Mao Q;Ni B;Wang Q;Wu Y
CD 4 + T细胞是HBV适应性免疫应答的主要调节因子。然而，CD 4 + T细胞亚群是异质性的，抗病毒剂如何影响不同的CD 4 + T细胞亚型仍然是未知的。为此，检测了替比夫定治疗前后B型肝炎患者CD 4 + T细胞亚型的标志性转录因子和细胞因子的表达。结果显示，在替比夫定诱导的HBV快速复制下降过程中，Th 17和Treg细胞的频率和相关细胞因子显著降低，而Th 2细胞的频率和相关细胞因子显著升高。Th 1细胞频率未观察到明显变化;但替比夫定治疗后IFN-γ表达上调，提示CHB患者IFN-γ的另一种细胞来源。统计分析表明，Th 17和Tr 1（Treg亚型）细胞是外周血CD 4 + T细胞中对替比夫定治疗52周最敏感的亚群。因此，Th 17和Tr 1细胞可能是替比夫定治疗期间反应性的合适且有效的预测因子。这些发现不仅提高了我们对肝炎发病机制的理解，而且有助于未来制定适当的治疗策略来控制病毒性肝炎。
CD4+ T cells serve as master regulators of the adaptive immune response to HBV. However, CD4+ T-cell subsets are heterogeneous, and it remains unknown how the antiviral agents affect the different CD4+ T cell subtypes. To this end, the expressions of signature transcription factors and cytokines of CD4+ T-cell subtypes were examined in hepatitis B patients before and after treatment with telbivudine. Results showed that, upon the rapid HBV copy decrease induced by telbivudine treatment, the frequencies and related cytokines of Th17 and Treg cells were dramatically decreased, while those for Th2 cells were dramatically increased. No obvious changes were observed in Th1 cell frequencies; although, IFN-γ expression was upregulated in response to telbivudine treatment, suggesting another cell source of IFN-γ in CHB patients. Statistical analyses indicated that Th17 and Tr1 (a Treg subtype) cells were the most sensitive subpopulations of the peripheral blood CD4+ T cells to telbivudine treatment over 52 weeks. Thus, Th17 and Tr1 cells may represent a suitable and effective predictor of responsiveness during telbivudine therapy. These findings not only improve our understanding of hepatitis pathogenesis but also can aid in future development of appropriate therapeutic strategies to control viral hepatitis.
登录
查看更多内容
影响因子：
13.5
作者：
Stoop, JN;van der Molen, RG;Janssen, HLA
通讯作者：
Janssen, HLA
DOI：
10.1084/jem.181.3.1047
发表时间：
1995-03-01
期刊：
The Journal of experimental medicine
影响因子：
--
作者：
Rehermann B;Fowler P;Sidney J;Person J;Redeker A;Brown M;Moss B;Sette A;Chisari FV
通讯作者：
Chisari FV
影响因子：
13.5
作者：
Hou, Jinlin;Yin, You-Kuan;Jia, Jidong
通讯作者：
Jia, Jidong
影响因子：
4.5
作者：
Gaeta, Giovanni Battista;Stornaiuolo, Gianfranca
通讯作者：
Stornaiuolo, Gianfranca
影响因子：
29.4
作者：
Dienstag, JL;Goldin, RD;Schiff, ER
通讯作者：
Schiff, ER